Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada

Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada

We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic A...

Full description

Bibliographic Details
Main Authors: Yacine Abed, Clément Fage, Patrick Lagüe, Julie Carbonneau, Jesse Papenburg, Donald C. Vinh, Guy Boivin
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2019-04-01
Series:Emerging Infectious Diseases
Subjects:
influenza B
resistance
neuraminidase
Gly407Ser
oseltamivir
zanamivir
Online Access:https://wwwnc.cdc.gov/eid/article/25/4/18-1554_article
id doaj-a708d162cf084442a4875e640e57d85a
record_format Article
spelling doaj-a708d162cf084442a4875e640e57d85a2020-11-25T01:55:01ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592019-04-0125483884010.3201/eid2504.181554Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, CanadaYacine AbedClément FagePatrick LagüeJulie CarbonneauJesse PapenburgDonald C. VinhGuy BoivinWe identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.https://wwwnc.cdc.gov/eid/article/25/4/18-1554_articleinfluenza BresistanceneuraminidaseGly407Seroseltamivirzanamivir
collection DOAJ
language English
format Article
sources DOAJ
author Yacine Abed
Clément Fage
Patrick Lagüe
Julie Carbonneau
Jesse Papenburg
Donald C. Vinh
Guy Boivin
spellingShingle Yacine Abed
Clément Fage
Patrick Lagüe
Julie Carbonneau
Jesse Papenburg
Donald C. Vinh
Guy Boivin
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
Emerging Infectious Diseases
influenza B
resistance
neuraminidase
Gly407Ser
oseltamivir
zanamivir
author_facet Yacine Abed
Clément Fage
Patrick Lagüe
Julie Carbonneau
Jesse Papenburg
Donald C. Vinh
Guy Boivin
author_sort Yacine Abed
title Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_short Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_full Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_fullStr Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_full_unstemmed Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
title_sort reduced susceptibility to neuraminidase inhibitors in influenza b isolate, canada
publisher Centers for Disease Control and Prevention
series Emerging Infectious Diseases
issn 1080-6040
1080-6059
publishDate 2019-04-01
description We identified an influenza B isolate harboring a Gly407Ser neuraminidase substitution in an immunocompromised patient in Canada before antiviral therapy. This mutation mediated reduced susceptibility to oseltamivir, zanamivir, and peramivir, most likely by preventing interaction with the catalytic Arg374 residue. The potential emergence of such variants emphasizes the need for new antivirals.
topic influenza B
resistance
neuraminidase
Gly407Ser
oseltamivir
zanamivir
url https://wwwnc.cdc.gov/eid/article/25/4/18-1554_article
work_keys_str_mv AT yacineabed reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT clementfage reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT patricklague reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT juliecarbonneau reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT jessepapenburg reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT donaldcvinh reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
AT guyboivin reducedsusceptibilitytoneuraminidaseinhibitorsininfluenzabisolatecanada
_version_ 1724985581846396928

Similar Items